Plasma concentration and disposition of buprenorphine after intravenous and intramuscular doses to baboons
- PMID: 7250147
- DOI: 10.1007/BF03189469
Plasma concentration and disposition of buprenorphine after intravenous and intramuscular doses to baboons
Abstract
Buprenorphine is a newly-developed strong analgesic. A selected ion monitoring method has been developed to measure its plasma levels over the concentration range 20-3000ng ml-1. Six baboons each received intravenous and intramuscular doses of buprenorphine hydrochloride at a level of 5mg/kg in a cross-over study. The mean peak plasma concentrations (+/-standard deviation) were 2290 +/- 357ng ml-1 and 805 +/- 416ng ml-1 respectively and the corresponding times to the peak levels were 4.0 +/- 1.5 minutes and 30.3 +/- 24.6 minutes suggesting the rapid release of the drug from intramuscular sites. Comparison of areas under the plasma concentration versus time curves to 24 hours after dosing showed the mean bioavailability of buprenorphine from the intramuscular doses was 70% of that from the reference intravenous doses.
Similar articles
-
Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis.Br J Clin Pharmacol. 1982 May;13(5):665-73. doi: 10.1111/j.1365-2125.1982.tb01434.x. Br J Clin Pharmacol. 1982. PMID: 7082534 Free PMC article. Clinical Trial.
-
Pharmacokinetic and pharmacodynamic modelling of intravenous, intramuscular and subcutaneous buprenorphine in conscious cats.Vet Anaesth Analg. 2013 Jan;40(1):83-95. doi: 10.1111/j.1467-2995.2012.00779.x. Epub 2012 Sep 24. Vet Anaesth Analg. 2013. PMID: 22998333 Clinical Trial.
-
Pharmacokinetics of buprenorphine hydrochloride following intramuscular and intravenous administration to American kestrels (Falco sparverius).Am J Vet Res. 2014 Aug;75(8):711-5. doi: 10.2460/ajvr.75.8.711. Am J Vet Res. 2014. PMID: 25061701
-
Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.Clin Ther. 2007 Aug;29(8):1620-31. doi: 10.1016/j.clinthera.2007.08.007. Clin Ther. 2007. PMID: 17919544 Clinical Trial.
-
Buprenorphine: a review of its pharmacological properties and therapeutic efficacy.Drugs. 1979 Feb;17(2):81-110. doi: 10.2165/00003495-197917020-00001. Drugs. 1979. PMID: 378645 Review.
Cited by
-
Buprenorphine Increases HIV-1 Infection In Vitro but Does Not Reactivate HIV-1 from Latency.Viruses. 2021 Jul 27;13(8):1472. doi: 10.3390/v13081472. Viruses. 2021. PMID: 34452338 Free PMC article.
-
Pharmacokinetics of 2 formulations of buprenorphine in macaques (Macaca mulatta and Macaca fascicularis).J Am Assoc Lab Anim Sci. 2013 Jan;52(1):48-56. J Am Assoc Lab Anim Sci. 2013. PMID: 23562033 Free PMC article.
-
The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users.Pharmacol Biochem Behav. 2014 Jul;122:299-306. doi: 10.1016/j.pbb.2014.04.012. Epub 2014 May 2. Pharmacol Biochem Behav. 2014. PMID: 24793093 Free PMC article. Clinical Trial.
-
Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users.Addict Biol. 2015 Jul;20(4):784-98. doi: 10.1111/adb.12163. Epub 2014 Jul 25. Addict Biol. 2015. PMID: 25060839 Free PMC article. Clinical Trial.
-
Pharmacokinetics of buprenorphine following intravenous and intramuscular administration in male rhesus macaques (Macaca mulatta).J Vet Pharmacol Ther. 2014 Oct;37(5):480-5. doi: 10.1111/jvp.12113. Epub 2014 Mar 25. J Vet Pharmacol Ther. 2014. PMID: 24666428 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources